EVQLV

Our mission is to leverage advances in computation to EVQLVe the cost and time of developing these life-changing therapies. EVQLV: verb \ ē-ˈvälv, -ˈvȯlv \ to change or develop - often into a better, more complex, or more advanced state; to upgrade over previous generations; an instruction to mature into an improved condition; the most common starting sequence for the first 5 amino acids of human antibody heavy chains. At EVQLV, we leverage our expertise in machine learning, computational biology, drug development, and software engineering to transform the pace, cost, and scale of antibody discovery. Our proprietary computational platform EVQLVes antibody discovery by generating diverse, fully-human antibodies. With over 75% of doctor's visits leading to a one-size-fits-all prescription, the scale and urgency of this oversight requires new ways of thinking.We envision a future where your doctor will design a medicine specifically for you - one that will work best for you, one that may only work for you. That is precisely what we work towards, everyday, here at EVQLV. Vikas Goyal is a biotech entrepreneur and investor, with a particular focus on corporate strategy, capital formation, and corporate partnerships for early-stage therapeutics companies. Our technology was built with you in mind, providing the flexibility to solve your specific antibody design challenges.